Which of the following anticancer drugs are competitive inhibitors of tyrosine kinase –
**Core Concept**
Tyrosine kinase inhibitors (TKIs) are a class of anticancer drugs that target the enzyme tyrosine kinase, which plays a crucial role in cell signaling pathways involved in cell growth, proliferation, and survival. Competitive inhibition of tyrosine kinase blocks the binding of ATP to the enzyme, thereby preventing the phosphorylation of tyrosine residues on target proteins.
**Why the Correct Answer is Right**
The correct answer is a specific TKI that competes with ATP for binding to the active site of the tyrosine kinase enzyme. This competition prevents the enzyme from phosphorylating its substrates, ultimately leading to the inhibition of cell proliferation and induction of apoptosis in cancer cells. The mechanism of action of this TKI is based on its ability to bind to the ATP-binding site of the enzyme, thereby blocking the access of ATP and preventing the phosphorylation of tyrosine residues.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is a different class of anticancer drugs that targets a different molecular mechanism.
**Option B:** This option is incorrect because it is a chemotherapeutic agent that works through a different mechanism of action, such as DNA damage or disruption of microtubule dynamics.
**Option C:** This option is incorrect because it is a targeted therapy that targets a different protein or pathway, such as the EGFR or VEGF pathways.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that TKIs are a class of anticancer drugs that can be used to treat a variety of cancers, including melanoma, lung cancer, and gastrointestinal stromal tumors (GISTs). TKIs can also be used in combination with other therapies to enhance their effectiveness.
**Correct Answer:** C.